Search results
Results from the WOW.Com Content Network
The fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase was approved for medical use in the United States in June 2020. [5] [10]The FDA's approval was based on the results of a non-inferiority study in participants with HER2-positive early breast cancer, which demonstrated the fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase had comparable efficacy and ...
Other severe side effects include heart failure, allergic reactions, and lung disease. [31] Use during pregnancy may harm the baby. [23] Trastuzumab works by binding to the HER2 receptor and slowing down cell replication. [31] Trastuzumab was approved for medical use in the United States in September 1998, and in the European Union in August 2000.
Pertuzumab is administered as an intravenous infusion in combination with trastuzumab and docetaxel as a first line treatment for HER2-positive metastatic breast cancer. [4] [3] It is also used in the same combination as a neoadjuvant (given to reduce the size of a tumor, prior to surgery or radiation) for HER2-positive early breast cancer; as of 2016 this use had not been shown to increase ...
The use of gender-affirming medical care for trans teens was rare between 2018 to 2022, according to a new study published in JAMA Pediatrics. Roughly 0.1% of gender non-conforming teens used ...
A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. With approximately 70% of American adults meeting the criteria for being obese or ...
In 2013, trastuzumab emtansine was approved in the United States for the treatment of adults with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. [18] [20] Referred to as T-DM1 during clinical research, trastuzumab emtansine was reviewed under the FDA's priority review ...
Image credits: Gilbert Flores/Variety/Getty Images Celebrity use and social media promotion of Ozempic have reportedly contributed to a shortage of the drug, which is intended to treat diabetes.
Trastuzumab/hyaluronidase, sold under the brand name Herceptin SC among others, is a fixed-dose combination medication for the treatment of HER2-overexpressing breast ...